- Company
- When will the Zyprexa lawsuit for damages be concluded?
- by Kim, Jin-Gu Oct 7, 2020 06:09am
- Interest is focused on whether the lawsuit for Zyprexa (Olanzapine) could be completed within this year. The range of compensation for patent infringement is determined according to the decision of the Supreme Court. If the Supreme Court sided with the original company Lilly Korea, it would be an obstacle to the early release of generics by d
- Company
- Next-gen flu drug Xofluza green lit in general hospitals
- by Eo, Yun-Ho Oct 6, 2020 06:25am
- The next generation influenza treatment ‘Xofluza (baloxavir)’ has been passed by major general hospitals for prescription. According to the related industry source, the Drug Committees at the ‘Big Five’ general hospitals like Seoul National University Hospital and Seoul St. Mary's Hospital green lit Xofluza, while the rest of the Big
- Company
- Mundipharma Korea appoints Hun Choi as the new CEO
- by An, Kyung-Jin Oct 6, 2020 06:24am
- Mundipharma announced on the 5th that it had appointed Hun Choi (46 yrs old), Managing Director, as the new CEO as of October 1. He graduated from Korea University Department of Chemistry and entered the pharmaceutical industry when he joined Novartis Korea in 2001. He served as a brand manager and sales manager, starting with a salespers
- Company
- Samsung Pharm won second trial with Samsung Electronics
- by Kim, Jin-Gu Oct 6, 2020 06:24am
- Samsung Pharm won the second round of the trademark dispute with Samsung Electronics over the name of 'Samsung'. Like the first trial, the second trial court admitted that Samsung Pharm had used the name Samsung for a longer time. The Patent Court of Korea ruled against the plaintiff in a lawsuit for invalidation of trademark registration
- Company
- Daewoong promotes the development of injectable hair loss tx
- by Nho, Byung Chul Oct 6, 2020 06:23am
- Daewoong is developing long-lasting hair loss treatments for male in earnest through open innovation that introduces promising external technologies. Daewoong (CEO Seng-Ho Jeon) signed a joint development contract with Inventage lab (CEO Ju Hee Kim), a drug delivery system platform venture company, on the 25th, and is conducting joint re
- Company
- Choline alfoscerate coverage reduction order suspended again
- by Chon, Seung-Hyun Oct 5, 2020 06:20am
- The court has once again approved to halt the administrative order on the cognitive enhancer ‘choline alfoscerate.’ Previously, the court has decided to suspend the order until the final ruling of the litigation, but another litigation case added 30 days to the already-approved order suspension. According to the industry sources on
- Company
- Merged BMS-Celgene to offer ERP after all
- by Eo, Yun-Ho Oct 5, 2020 06:20am
- Initially merged with almost no downsizing, Bristol-Myers Squibb (BMS) and Celgene have ultimately decided to slim down the organization in South Korea. According to the pharmaceutical industry sources, BMS Korea has recently decided to issue the Early Retirement Program (ERP) as a result of acquiring Celgene. The staff reduction wou
- Company
- Ildong is accelerating the development of Lasmiditan
- by Kim, Jin-Gu Sep 29, 2020 06:20am
- Ildong is accelerating the development of a new class of migraine treatment 'Lasmiditan'. A large-scale phase III clinical trial is in progress, close to 300 as a bridged clinical trial, and it is confirmed that the registration of subjects has recently been completed. According to the pharmaceutical industry on the 25th, Ildong recent
- Company
- Korean rare disease drug Hunterase market share surges
- by An, Kyung-Jin Sep 29, 2020 06:20am
- Developed with South Korean-made rare disease treating technology, Hunterase (idursulfase-β) continues to top the market. The treatment’s market share gap with Elaprase (idursulfase) that used to dominate the Hunter syndrome market has tripled as Hunterase maintains market share of over 70 percent. While the treatment is generating signifi
- Company
- Pfizer Korea launches Cresemba in Korea
- by Eo, Yun-Ho Sep 28, 2020 06:20am
- Pfizer Korea launched Cresemba (Isavuconazole), an invasive fungal infection treatment in Korea. Cresemba is an antifungal drug approved for the treatment of invasive aspergillosis in adults over 18 years of age and invasive mucormycosis, which is not suitable for administration of Amphotericin B in adults over 18 years of age, and obtain
